A planning study of proton therapy dose escalation for non-small cell lung cancer.

In non-small-cell lung cancer (NSCLC), improving local control through radiotherapy dose escalation might improve survival. However, a photon-based RCT showed increased organ at risk dose exposure and worse overall survival in the dose escalation arm. In this study, intensity-modulated proton therapy plans with dose escalation to the primary tumour were created for 20 NSCLC patients. The mediastinal envelope was delineated to spare structures around the heart. It was possible to increase primary tumour dose up to 74.0 Gy without a significant increase in organ at risk doses and predicted toxicity.

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: No specific funding related to this project was obtained. The Department of Radiation Oncology of the University Medical Center Groningen has research contracts with IBA, RaySearch, Siemens, Elekta, Leonia, and Mirada and has received grants from Dutch Cancer Society and EU. Prof. dr. J.A. Langendijk is a member of the Global Scientific Advisory Board of IBA and a member of the RayCare International Advisory Board of RaySearch. He has given presentations for local scientific meetings for IBA. Payments in all cases have been made to UMCG Research BV. Prof. dr. J.A. Langendijk is the chair of the Netherlands Society for Radiation Oncology.